Insider Transactions in Q3 2022 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-10.64%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+13.73%
|
-
|
|
Jul 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.42%
|
$15,657
$3.01 P/Share
|
|
Jul 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+6.08%
|
-
|
|
Jul 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-5.4%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+7.3%
|
-
|
|
Jul 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-4.34%
|
$2,580
$3.01 P/Share
|
|
Jul 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.94%
|
-
|
|
Jul 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-12.06%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+15.41%
|
-
|